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Abstract: In the central nervous system omega-3 fatty acids modulate cell signaling and affect
dopaminergic and serotonergic pathways. On this basis, a new application for omega-3 fatty acids
has been proposed, concerning the treatment of several psychiatric disorders. The present article
is an update of a previous systematic review and is aimed to provide a complete report of data
published in the period between 1980 and 2019 on efficacy and tolerability of omega-3 fatty acids in
psychiatric disorders. In July 2019, an electronic search on PUBMED, Medline and PsychINFO of
all RCTs, systematic reviews and meta-analyses on omega-3 fatty acids and psychiatric disorders
without any filter or MESH restriction was performed. After eligibility processes, the final number of
records included in this review was 126. One hundred and two of these studies were RCTs, while 24
were reviews and meta-analyses. The role of omega-3 fatty acids was studied in schizophrenia,
major depression, bipolar disorder, anxiety disorders, obsessive-compulsive disorder, post-traumatic
stress disorder, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, eating
disorders, substance use disorder and borderline personality disorder. The main evidence of the
efficacy of omega-3 fatty acids has been obtained in treating depressive symptoms in patients with
major depression and, to a lesser degree, bipolar depression. Some efficacy was also found in early
phases of schizophrenia in addition to antipsychotic treatment, but not in the chronic phases of
psychosis. Small beneficial effects of omega-3 fatty acids were observed in ADHD and positive
results were reported in a few trials on core symptoms of borderline personality disorder. For other
psychiatric disorders results are inconsistent.
Keywords: polyunsaturated fatty acids; omega-3 fatty acids; psychiatric disorders; randomized
controlled trials; efficacy; adverse effects
1. Introduction
The role of polyunsaturated fatty acids (PUFAs) in human health acquired growing interest in
the last decades. The most important classes of PUFAs are the omega-3 (ω-3) fatty acids, including
α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and omega-6
(ω-6) fatty acids, including linoleic and arachidonic acid. The beneficial proprieties of omega-3
fatty acids on inflammatory, cardiovascular and the nervous system are recognized by several
investigations [1–4]. To date, the mechanisms underlying the effects of PUFAs are partially unknown.
PUFAs are important components of phospholipids and cholesterol esters of the neuronal cell
membrane, especially of dendritic and synaptic membranes. The rationale for the use of these new
agents in psychiatric disorders stemmed from their primary action in producing modifications of the
phospholipid fatty acid composition of the synaptic membrane and modulation of second messengers
cascade [5–7]. In the brain, these agents modulate brain cell signaling, including dopaminergic and
serotonergic pathways [8–10]. A well-balanced omega-3/omega-6 ratio is fundamental for development
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and functioning of the central nervous system. In particular, EPA and DHA constitute principal
regulating factors of neurogenesis, cell survival and neurotransmission [2,11]. In recent years the effects
of PUFAs were investigated in several psychiatric disorders. The role of EPA and DHA were studied
in psychosis, major depression, bipolar disorder, anxiety disorders, obsessive-compulsive disorder,
post-traumatic disorder, eating disorders, attention deficit hyperactivity disorder (ADHD), autism
spectrum disorders, substance abuse and borderline personality disorder. The present review is an
update of our previous systematic review [10] aimed to provide a complete report of the evidence from
data published in the period ranging between 1980 and 2019 on efficacy and tolerability of omega-3
fatty acids in psychiatric disorders. The objective is to establish whether data collected in trials of
PUFAs in the treatment of psychiatric disorders, particularly those collected in the last years, provide
evidence to support their indications in specific diagnoses.
2. Methods
In July 2019, an electronic search on PUBMED, Medline and PsychINFO of all RCTs on omega-3
fatty acids and psychiatric disorders without any filter or MESH restriction was performed, using the
following search string: “omega-3 fatty acids” and “psychiatric disorders” or “polyunsaturated
fatty acids” and “psychiatric disorders” or “eicosapentaenoic acid” and “psychiatric disorders” or
“docosaexaenoic acid” and “psychiatric disorders” or “ a` linolenic acid” and “psychiatric disorders” or
“higly unsaturated fatty acids” and “psychiatric disorders” or “omega-3 fatty acids” and “schizophrenia”
and “psychosis” and “depression” and “bipolar disorder” and “anxiety” and “post-traumatic disorder”
and “attention deficit hyperactivity disorder” and “autism” and “eating disorders” and “impulsivity”
and “personality disorders” and “substance disorders”. This string guaranteed a highly sensitive
search, limiting the spelling selection of published indexed works. This logical connective led to a highly
specific search that selected mostly works on the topic. We included controlled trials, meta-analyses
and reviews published until July 2019. Publications had to concern efficacy and tolerability of omega-3
fatty acids in mental disorders as the principal issue. Publications written in a language other than
English were excluded.
3. Results
The search provided 2751 records. Eligibility status for all retrieved articles was determined in
two stages. First, all studies were screened based upon title and abstract. The overlapping studies
(2401) were excluded. Second, papers passing the initial title and abstract screen (350) were reviewed
based upon the full manuscript. 158 were excluded because they did not fit the objective of the review,
45 because they were not written in English and 21 for the lack of the complete manuscript. The final
number of records included was 126 (see the flow chart; Figure 1). Among these 102 were RCTs,
while 24 were reviews/meta-analyses. The predominant ethnicity was Caucasian. Drop-out rates were
acceptable (<20%). The majority of studies had a retention ≥ 80%.
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Figure 1. Literature search flowchart. 
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that both groups received and that could have hidden the effects of omega-3 fatty acids. Results are 
summarized in Table 1.  
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4. Discussion
4.1. Omega-3 Fatty Acids in Schizophrenia
In both chronic and non-medicated first episode patients with psychosis it was observed that
highly unsaturated fatty acids levels are reduced in the erythrocyte membranes and in the post-mortem
brain tissue in comparison to healthy controls [12–15]. A decrease of the proportion of omega-3 fatty
acids in the cellular membranes was associated with worse functioning also prior to the onset of
psychosis [15] and could be linked with poor therapeutic response and greater severity of symptoms
in patients with schizophrenia [16,17]. Schizophrenia is a psychotic disorder defined by abnormalities
in five symptom domains: Delusions, hallucinations, disorganized thinking, disorganized behaviors
and negative symptoms. The disturbance must be present continuously for more than six months and
has usually a chronic course.
In order to evaluate the effects of omega-3 fatty acids in the different phases of schizophrenia,
investigations were conducted in subjects at high risk to develop psychosis, patients with first psychotic
episode and patients in chronic phase.
Five publications concerning the efficacy of omega-3 fatty acids in high-risk subjects for psychosis
are available [18–22]. Four of these presented data from the same sample [18–21] and supported the
utility of EPA and DHA (doses ranged between 1.2 g/day and 2.2 g/day) compared with the placebo in
reducing the rate of progression in psychosis in short-term (12 weeks) and long-term (mean 6.7 years)
studies. On the other hand, a multicentre double-blind randomized study [22] comparing omega-3
fatty acids plus cognitive-behavioral case management (CBCM) or placebo plus CBCM in a wide
sample of young subjects at risk for developing psychosis reported an improvement in transition rates
to psychosis with no significant differences between the two groups. A possible explanation could be
that amelioration is due to the effect of CBCM and antidepressants that both groups received and that
could have hidden the effects of omega-3 fatty acids. Results are summarized in Table 1.
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Table 1. Double-blind controlled trials of polyunsaturated fatty acids (PUFAs) as add-on strategy in
the treatment of schizophrenia.
High-Risk Psychosis
Study Drugs and Dose Sample TreatmentDuration Results
Amminger
et al., 2010
[18]
EPA
700 mg/day +
DHA
480 mg/day
81 individuals
UHR 12 weeks
↓ progression in psychosis in
young UHR patients
Amminger
et al., 2013
[19]
EPA
700 mg/day + DHA
480 mg/day +
7.6 mg vit. E
81 young
individuals at UHR 12 weeks
↓ positive symptoms, negative
symptoms and general
symptoms,
↑ level of functioning
Amminger
et al., 2015
[20]
EPA
700 mg/day +
DHA
480 mg/day
81 young
individuals at UHR 12 weeks
↓ both risk of progression to
psychotic disorder and
psychiatric morbidity
Smesny
et al., 2014
[21]
EPA
700 mg/day +
DHA
480 mg/day
81 young
individuals at UHR 12 weeks
normalizing PLA2 activity and
d-6-desaturase-mediated
metabolism of o-3 and o-6
PUFAs
McGorry
et al., 2017
[22]
EPA
840 mg/day +
DHA 560 mg/day
+ CBCM
304 individuals
UHR 24 weeks
not effective under conditions
where evidence-based
psychosocial treatment is
available
First-episode Psychosis
Study Drugs and Dose Sample TreatmentDuration Results
Berger et al.,
2007
[23]
Ethyl-EPA
3 g/day 69 patients 12 weeks accelerated treatment response
Berger et al.,
2008
[24]
EPA 2 g/day 24 patients 12 weeks ↓ of negative symptoms
Wood et al.,
2010
[25]
EPA 2 g/day 17 patients 12 weeks
increased water in hippocampal
tissues and positive effect on
negative symptoms
Emsley
et al., 2014
[26]
EPA 2 g/day +
DHA 1 g/day +
α-LA 300 mg/day
33 patients 2 years relapse prevention of psychoticsymptoms
Pawelzcyk
et al., 2016
[27]
EPA + DHA
2.2 g/day 71 patients 26 weeks
↓ psychotic symptoms
measured with PANSS
↓ depressive symptoms
↑ level of functioning
Pawelzcyk
et al., 2017
[28]
EPA + DHA
2.2 g/day 71 patients 26 weeks
improved PANSS negative and
general symptoms, along with
global functioning
Pawelzcyk
et al., 2018
[29]
EPA + DHA
2.2 g/day 71 patients 26 weeks
↑ level of telomerase in
peripheral blood cells with ↓
depressive symptoms
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Table 1. Cont.
Stable Schizophrenia
Study Drugs and Dose Sample TreatmentDuration Results
Peet et al.,
2001
[30]
EPA or DHA
2 g/day 45 patients 12 weeks
↓ psychotic symptoms
measured with PANSS in the
group treated with EPA
Peet and
Horrobin,
2002
[31]
E-EPA
1–4 g/day 115 patients 12 weeks
↓ positive symptoms
measured with PANSS,
↓ depressive symptoms
Emsley
et al., 2002
[32]
ethyl-EPA
3 g/day 40 patients 12 weeks
↓ positive symptoms
and negative symptoms
measured with PANSS
Emsley
et al., 2006
[33]
ethyl-EPA
2 g/day 77 patients 12 weeks
no efficacy on specific psychotic
symptoms
Jamilian
et al., 2014
[34]
1 g/day 60 patients 8 weeks ↓ psychotic symptomsmeasured with PANSS
Fenton
et al., 2001
[35]
ethyl-EPA
3 g/day 87 patients 16 weeks
no significant differences in
positive, negative symptoms,
mood or cognition
Bentsen
et al., 2013
[36]
ethyl-EPA
2 g/day 99 patients 16 weeks
↓ impairment of the course of
psychosis
Qiao et al.,
2018
[37]
DHA 360 mg/day +
EPA 540 mg/day 50 patients 12 weeks
↓ violence, but no improvement
in positive and negative
symptoms
Robinson
et al., 2019
[38]
EPA 740 mg and
DHA 400 mg/day 50 patients 16 weeks
↓ confusion, anxiety, depression,
irritability and tiredness/fatigue
In the first episode of psychosis (FEP), seven publications with data from three clinical studies have
examined the effects of omega-3 fatty acids [23–29]. Trials performed by Berger and colleagues [23] and
Pawelczyk and colleagues [27] tested EPA and DHA in adjunction to antipsychotics, while Emsley’s
trial administered fatty acids as single therapy [26]. All studies used pure EPA or a fatty acids
composition with high EPA. Duration of these trials ranged between 12 and 26 weeks. PUFAs dosages
ranged between 2 and 3 g/day. In the study performed by Emsley et al. omega-3 fatty acids were
administered to prevent relapse during antipsychotic discontinuation in remitted FEP followed for
2 years.
Reports from the two studies by Berger and Pawelczyk [23–25,27–29] reported encouraging
data on EPA and DHA in first episode of psychosis in terms of symptoms reductions and
neurobiological changes. Findings showed an improvement of general, psychotic, negative and
depressive symptoms [24,25,27,28], a reduction of deterioration of hippocampus tissues with a positive
effect on negative symptoms [25], a decrease of oxidative stress status of plasma with a positive effect on
global and negative symptoms [28] and an increase of telomerase levels in peripheral blood cells with
a positive effect on depressive symptoms and severity of illness [29]. RCT performed by Berger et al.,
2008 was extended until 24 weeks of omega-3 fatty acids supplementation [24] and reported significant
improvements in both symptoms and real-world functioning. Emsley’s study [26] did not show
significant benefit for symptoms and functioning or relapse rate after antipsychotic discontinuation.
Int. J. Mol. Sci. 2019, 20, 5257 6 of 32
This study was rather different from other RCTs as tested the efficacy of fatty acids in monotherapy
(with no antipsychotic support) in relapses prevention. Results are summarized in Table 1.
Nine RCTs were performed in patients with stable schizophrenia [30–38]. Seven studies showed a
positive effect of omega-3 fatty acids on several symptom domains of schizophrenia [30–32,34,36–38],
while two trials [33,35] failed to observe significant advantages with PUFAs supplementation.
The majority of studies tested the efficacy of EPA in adjunction to antipsychotics and only three
studies [30,37,38] evaluated the effects of combination of EPA and DHA as adjuvant antipsychotic
treatment. Duration of studies ranged between 8 and 16 weeks. Daily doses of PUFAs were
from 0.9 to 4 g. EPA has been found superior than the placebo and also than DHA in reducing
positive symptoms [30–32,34], negative symptoms [32], depressive symptoms [31,38] and anxious
symptoms [38] of schizophrenia. One study indicated that omega-3 fatty acids were useful in reducing
violent behaviors in schizophrenia [37]. Moreover, supplementation with EPA showed a significant
decrease of impairment of the course of psychosis [36].
In spite of these encouraging data, it is hard to draw any conclusions on medium- and long-
term efficacy of omega-3 fatty acids in stable schizophrenia. In fact, trials performed in this phase of
illness have too short a duration to establish long lasting effects of these agents. It is interesting to
notice that the majority of studies found a positive effect of pure EPA or a fatty acids composition with
predominant EPA, at least when added to a stable antipsychotic treatment. On the contrary, the study
by Peet and colleagues [30] tested pure DHA without finding significant effects.
Several reviews and meta-analyses [39–45] of RCTs concerning the efficacy of omega-3 in psychosis
concluded that the evidence in favor of omega-3 fatty acids as psychotropic agents in schizophrenia is
preliminary and findings remain inconclusive as available trials suffer from some significant limitations,
including rather small sample size, heterogeneity in diagnosis and omega-3 combinations and doses
and short duration of the majority of studies. Collected data suggested that EPA or a composition of
fatty acids with high EPA could be more effective in the early phases of schizophrenia than in chronic
phases of the disorder. Studies using pure or predominant EPA in high-risk subjects are lacking and
should be performed. Results are summarized in Table 1.
4.2. Omega-3 Fatty Acids in Major Depressive Disorder
Some investigations reported that patients with major depressive disorder (MDD) have a lower
level of EPA and DHA in their peripheral tissues (plasma, serum and red blood cells) than control
subjects [46,47]. A dietary intake of fish or PUFAs could be linked to a decreased risk of major
depressive disorder (MDD) [48–53] and improvement in white matter integrity [54]. Moreover,
the anti-inflammatory capacity of omega-3 fatty acids, particularly EPA, could be crucial to prevent
depression development [55]. Major depressive disorder is an episodic, recurrent disorder characterized
by evident depression of mood and significant impairment of cognitive abilities and neuro-vegetative
functions that last more than two weeks, but usually several months. Remission occurs between
two episodes.
Thirty-six studies were published in order to evaluate the efficacy of EPA and DHA in mild and
moderate unipolar depression [56–91]. Among these, eight were performed in women with perinatal
depression [58,64,66,68,71,81,82,88]. Three studies were conducted in adolescents [62,86,87] and three
trials in elderly depressive patients [72,73,75]. To limit the heterogeneity of this review, we decided to
exclude trials on the efficacy of PUFAs in treating MDD in subjects with medical comorbidity and trials
in which depressive symptoms were secondary to dementia and other neurological diseases. Fatty acids
were administered both as monotherapy and as supplementation to ongoing pharmacotherapy or
psychotherapy. The majority of studies tested the efficacy of combination of EPA and DHA. Three trials
evaluated the efficacy of single EPA [56,57,70], one study compared single EPA and combination of
EPA and antidepressants [65], two trials compared single DHA and placebo [58,59]. Duration of RCTs
ranged between 4 and 16 weeks. Doses ranged from 0.4 to 4.4 g/day of EPA and from 0.2 to 2.4 g/day
of DHA. To assess the level of depressive and depression-related symptoms rather heterogeneous
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evaluation instruments were used (Hamilton Depression Rating Scale, Montgomery-Asberg Depression
Rating Scale, Beck Depression Inventory, Childhood Depression Rating Scale, Childhood Depression
Inventory, Edinburgh Postnatal Depression Scale, Geriatric Depression Scale and Hopkins Symptom
Checklist Depression Scale).
Concerning perinatal depression, available evidence consists of a prevalence of negative findings.
RCTs performed in healthy pregnant women [68,71] or in pregnant women with major depressive
disorder [64,66] did not find any significant effects on depression scores after childbirth. In a similar
way, no significant therapeutic effect was observed in women with a history of post-partum depression
treated from pregnancy to postpartum (up to 6 months) or after childbirth with EPA and DHA [58,59,81].
It should be noticed that two of these studies investigated single DHA and DHA has been found
ineffective in treating depressive symptoms. Only two RCTs reported that combination of EPA and
DHA supplementation during pregnancy could lower depression scores after childbirth [82,88].
In adolescence, two studies reported the efficacy of combination of EPA and DHA in reducing
depressive symptoms [62] and behavioral symptoms, such as hyperactivity, impulsivity and opposition
that often occur with depression in youths [86]. On the contrary one RCT [87] concluded that in
adolescents with major depression omega-3 fatty acids did not appear superior to the placebo.
In elderly age, two studies of patients with mild to moderate depression showed an improvement
of mood after treatment with low doses of both EPA and DHA [72,73,75].
Across other RCTs (21) that have been conducted in unipolar depressed adult patients (age ranged
between 20 and 65 years), fifteen [56,57,60,65,70,74,77–80,83,85,89–91] trials found that EPA and DHA
were efficacious in reducing depressive symptoms, while seven [59,61,63,67,69,76,84] studies obtained
negative results. Studies that evaluated specifically the efficacy of EPA versus placebo [70] and EPA
plus DHA versus placebo [85] showed a reduction of depression in patients treated with both PUFAs,
but results did not reach statistical significance.
Two studies reported a significant improvement of depressive symptoms in patients undergoing
antidepressant therapy treated with supplementation of single EPA at doses ≤ 2 g/day [56,57]. Only one
study on suplementation of single DHA failed to show a significant effect of this agent on mood
modulation [59].
The majority of trials compared the combination of EPA and DHA in addition to standard
antidepressant therapy or in monotherapy versus placebo. Two studies [61,63] obtained no significant
improvement in symptoms of depression in patients who were treated with similar doses of EPA and
DHA (ranging from 2 to 3 g/day) and two studies [67,76] confirmed inefficacy of these agents on both
depression and cognitive functions. In other investigations, omega-3 fatty acids supplementation was
found superior to the placebo in ameliorating not only depressive symptoms [74], but also anxiety,
sleep and regulation of emotions [89]. In particular, a combination of higher dose of EPA with lower
dose of DHA revealed a beneficial effect on mood [72,79], while the opposite combination (lower EPA
and higher DHA) failed to improve symptoms [60,61,63,67,83,85]. Studies that investigated the efficacy
of EPA compared with DHA reported mixed results. In fact, one trial showed greater efficacy of EPA
over DHA and over the placebo as an adjunctive treatment in mild and moderate depression [80],
while another study failed to demonstrate a superior antidepressive effect of either omega-3 fatty
acids (DHA and EPA) over the placebo [84]. One study [91] demonstrated that subjects with major
depression and a high number of inflammatory biomarkers had a better response to EPA than the
placebo and a lower response to DHA than the placebo. Other RCTs evaluated the effect of EPA or EPA
plus DHA in monotherapy or in association with antidepressants drugs (fluoxetine and citalopram).
Results suggested that the efficacy of EPA and fluoxetine combination was superior to either of them
alone (fluoxetine or EPA) in reducing depressive symptoms [65]. The add-on therapy to citalopram
with EPA, DHA and other PUFAs was found significantly more efficacious in reducing depression
than single therapies, but with no changes in rapidity of initial antidepressant response [77].
The dedicated section “Complementary and Alternative Medicine Treatment” of the Canadian
Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of
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adult with major depressive disorder included the results of four meta-analyses [92–95] and two
systematic reviews [96,97]. One meta-analysis [92] did not find any benefit from omega-3 fatty
acids treatment; one meta-analysis [94] and one review [97] reported discordant and equivocal
outcomes; one meta-analysis [95] stated positive outcomes for EPA and DHA as monotherapy; and one
meta-analysis [93] and one review [96] found a positive outcome of PUFAs as adjunctive therapy.
The first meta-analysis by Bloch and Hannestad [92] presented negative conclusions, but this result was
likely influenced by the inclusion of a study in which strict criteria for depression were not met [67].
If this study is not considered, the meta-analysis has positive results.
On the basis of these findings, CANMAT guidelines concluded that PUFAs reached level 1
evidence (meta-analysis with narrow confidence intervals and/or two or more RCTs with adequate
sample size, preferably placebo controlled) of efficacy but, because of the inconsistency in the findings,
are recommended as second-line monotherapy for mild to moderate MDD and as adjunctive therapy
to antidepressants for moderate to severe MDD [98]. After publication of the CANMAT guidelines,
other five systematic reviews were published [99–103]. Authors concluded that quality of evidence was
not so good to determine the effectiveness on PUFAs in treatment of MMD. However, there is a general
agreement to consider omega-3 PUFAs as a promising supplementation therapy in combination with
antidepressants or in monotherapy. A focal point to be considered is the different efficacy of the two
fatty acids more commonly tested, EPA and DHA. Two meta-analyses published by Martins [104]
and Sublette and colleagues [105] reported that EPA is likely more effective than DHA in treating
depression and that combination of the two fatty acids has antidepressant effects when the proportion
of EPA is more than 60%. So, available evidence indicates that pure or predominant EPA, but not pure
DHA, is effective in major depression.
In conclusion, supplementation with PUFAs in patients with major depression seems useful in
improving depressive symptoms, but findings are not univocal. Data in adolescents and elderly patients
are promising, but more studies investigating sufficiently large samples are needed. On the contrary,
EPA and DHA failed to show significant effects on depressive symptoms in perinatal depression.
Data of studies of major depression are summarized in Table 2.
Table 2. Double-blind controlled trials of polyunsaturated fatty acids (PUFAs) in the treatment of
depressive disorders.
Study Drugs and Dose Sample TreatmentDuration Results
Nemets
et al., 2002
[56]
ethyl-EPA
2 g/day 20 patients 4 weeks
↓ depressive symptoms measured
with HDRS from the second week of
treatment
Peet and
Horrobin,
2002
[57]
ethyl-EPA
1, 2 or 4 g/day
add-on standard antidepressant
treatment
70 patients resistant
to antidepressant
treatment
12 weeks
↓ depressive symptoms measured
with HDRS, MADRS and BDI in the
group treated with 1 g/day of PUFAs
LIorente
et al., 2003
[58] DHA 0.2 g/day monotherapy
99 healthy
pregnant women 16 weeks no effect on depression
Marangell
et al., 2003
[59]
add on to standard therapy
DHA 2 g/day monotherapy
36 depressed
patients 12 weeks no significant differences
Su et al.,
2003
[60]
ethyl-EPA
4.4 g/day + DHA 2.2 g/day
add-on existing antidepressant
treatment
22 patients 8 weeks ↓ depressive symptoms measuredwith HDRS
Silvers et al.,
2005
[61]
EPA 0.6 g/day +DHA 2.4 g/day
added to standard therapy 77 MDD patients 12 weeks
no evidence that n-3PUFAs improved
mood compared to placebo.
Mood improved in both groups
within the first 2 weeks of the study
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Study Drugs and Dose Sample TreatmentDuration Results
Nemets
et al., 2006
[62]
ethyl-EPA
0.4 g/day + DHA 0.2 g/day
20 patients 6–12
years-old 16 weeks
↓ depressive symptoms measured
with CDRS, CDI and CGI
Greyner
et al., 2007
[63]
EPA 0.6 g/day + DHA 2.2 g/day
add to standard therapy 83 MDD patients 16 weeks no significant differences
Freeman
et al., 2008
[64]
EPA 1.1 g/day + DHA 0.8 g/day 59 women 8 weeks no benefit on perinataldepressive symptoms
Jazayeri
et al., 2008
[65]
EPA 1 g/day versus fluoxetine
20 mg/day 60 patients 8 weeks
↓ depressive symptoms in
both groups
Rees et al.,
2008
[66]
ethyl-EPA
0.4 g/day + DHA 1.6 g/day
26 pregnant
patients 6 weeks no benefits on depressive symptoms
Rogers
et al., 2008
[67]
EPA 0.63 g/day + DHA
0.85 g/day monotherapy
218 mild to
moderate
depressed patients
untreated
12 weeks
n-3PUFAs not have beneficial or
harmful effects on mood in mild to
moderate depression.
Doornbos
et al., 2009
[68]
DHA 0.22 g/day or DHA
0.22 g/day + AA (0.22 g/day
arachidonic acid) monotherapy
119 healthy
pregnant women 28 weeks
red blood cell DHA, AA and
DHA/AA ratio did not correlate with
EPDS or blues scores
Lucas et al.,
2009
[69]
EPA 1.05 g/day + DHA
0.25 g/day mono-therapy
120 patients with
psychological
distress with or
without MDD in
comorbidity
8 weeks no significant differences
Mischoulon
et al., 2009
[70]
EPA 1 g/day + (+0.2% dl
alphatocopherol) monotherapy 57 MDD patients 8 weeks
↓ depressive symptoms assessed with
HDRS, but no statistical significance
Makrides
et al., 2010
[71]
DHA-rich tuna oil capsules
0.5 g/day mono therapy
2399 healthy
pregnant women at
21 weeks’ gestation
women received
assigned capsules
daily, from study
entry until birth
of their child
DHA during pregnancy did not lower
levels of postpartum depression
Rondanelli
et al., 2010,
2011
[72,73]
EPA 1.67 g/day + DHA
0.83 g/day added to existing
antidepressant treatment
46 elderly female
residents in a
nursing home
8 weeks
↓ depressive symptoms
assessed with GDS,
improvement of phospholipids fatty
acids profile
Lespérance
et al., 2011
[74]
EPA 1.05 g/day + DHA
0.15 g/day
432 patients with a
major depressive
episode
8 weeks
↓ depressive symptoms only for
patients without comorbid anxiety
disorders
Tajalizadekhoob
et al., 2011
[75]
EPA 0.18 g/day + DHA 0.12
g/day add to standard therapy
in 55 patients while in 11
monotherapy
66 patients with
mild-to moderate
depression aged >
66 years
24 weeks
low-dose n-3PUFAs have some
efficacy in mild to moderate
depression
Antypa
et al., 2012
[76]
EPA 1.74 g/day+ DHA 0.25
g/day added to standard therapy
71 patients with
history of at least
one MDD
4 weeks
no significant effects on memory,
attention, cognitive reactivity and
depressive symptoms
Gertsik
et al., 2012
[77]
EPA 0.9 g/day + DHA 0.2 g/day
+ other n-3 PUFAs (0.1 g/day)
added to citalopram
42 MDD patients
taking citalopram 9 weeks
significantly greater improvement in
HDRS scores
Krawczyk
et al., 2012
[78]
EPA 2.2 g/day + DHA 0.7 g/day
+ GLA (0.24 g/day) + vit. E
added to standard therapy
21 patients with
severe episode of
treatment resistant
recurring
depression
8 weeks n-3PUFAs significantly improvedHDRS scores
Rizzo et al.,
2012
[79]
EPA/DHA 2.1/2.5 g of n3-PUFA
monotherapy
46 MMD patients
(only women > 66
years old)
8 weeks
mean GDS score and AA/EPA ratio, in
whole blood and RBC membrane
phospholipids, were
significantly lower
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Table 2. Cont.
Study Drugs and Dose Sample TreatmentDuration Results
Mozzafarri
Khoshari
et al., 2013
[80]
EPA 1 g/day or DHA 1 g/day
added to standard therapy
81 mild to
moderate
depressed patients
12 weeks ↓ HDRS score compared with those inthe DHA or placebo groups
Mozurkewich
et al., 2013
[81]
EPA 1.06 g/day+ DHA 0.27
g/day or EPA 0.18 g/day + DHA
0.9 g/day mono-therapy
126 healthy
pregnant women 6-8 weeks
no differences between groups in BDI
scores or other depression endpoints
Judge et al.,
2014
[82]
DHA 0.3 g/day 42 healthypregnant women 8 weeks
↓ depressive symptoms assessed
with PDSS
Ginty et al.,
2015
[83]
EPA + DHA 1.4 g/day
monotherapy
23 depressed
patients 3 weeks
n-3PUFAs group had a significant
reduction in BDI scores over time
Mischoulon
et al., 2015
[84]
EPA 1 g/day or DHA 1 g/day 196 patients 8 weeks EPA and DHA were not superiorto placebo
Park et al.,
2015
[85]
EPA 1140 g/day + DHA 0.6
g/day add to standard therapy 35 MDD patients 12 weeks no significant differences
Young et al.,
2017
[86]
PEP + EPA 1.4g/day + DHA
0.2 g/day + 0.4 g/day other
72 patients 7–14
years old 12 weeks
↓ co-occurring behaviour symptoms
in youth with depression.
Gabbay
et al., 2018
[87]
2:1 ratio of EPA to DHA: Initial
dose of 1.2 g/day. Doses were
raised in increments of 0.6 g/day
every 2 weeks (maximum
possible dose of 3.6 g/day,
combined EPA 2.4 g +
DHA 1.2 g)
51 psychotropic
medication-free
adolescents with
MDD aged
12–19 years
10 weeks n-3PUFAs do not appear to besuperior to placebo.
Jahangard
et al., 2018
[89]
n-3 PUFAs (1000 mg/day) +
sertraline (50–200 mg/day) 50 MDD patients 12 weeks
↓ depression, anxiety, sleep and
patients’ competencies to regulate
their emotions.
Tayama
et al., 2019
[90]
DHA 500 mg/day + EPA
1000 mg/day
20 patients with
mild to moderate
depression
12 weeks no significant differences
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ethyl-EPA = ethyl-eicosapentaenoic
acid; AA: Arachidonic acid; CDRS = Childhood Depression Rating Scale; CDI = Childhood Depression Inventory;
EPDS = Edinburgh Postnatal Depression Scale; GDS = Geriatric Depression Scale; ↓ = decrease of; ↑ = increase
of; MDD: Major depressive disorder; HDRS: Hamilton Depression Rating Scale; BDI: Beck Depression Inventory;
PDSS = Postpartum Depression Screening Scale; PEP= Individual-Family Psychoeducational Psychotherapy.
4.3. Omega-3 Fatty Acids in Bipolar Disorder
A growing number of investigations reported that inflammatory mechanisms are important
mediator of pathophysiology in bipolar disorder [7,106]. Omega-3/omega-6 PUFAs ratio, implicated
in processes of inflammation, is often unbalanced in patients with affective disorders. In particular,
in subjects with a diagnosis of bipolar disorder lower erythrocyte membrane levels of omega-3 fatty
acids have been observed [107,108]. Bipolar disorder is the modern definition of the classic concept of
manic-depressive psychosis. It is characterized by manic or hypomanic episodes with an abnormal state
of euphoria or excitement and in most cases by alternating major depressive episodes. Free intervals
between episodes are often present and last for varying periods.
Five RCTs were conducted in order to verify the effect of supplementation with EPA, DHA and their
combination in bipolar disorder in addition to mood stabilizing and antipsychotic therapies [109–112].
One RCT tested EPA plus DHA as monotherapy versus placebo [113] and one study evaluated the
efficacy of alfa linolenic acid (ALA) in addition to other psychotropic medications in children and
adolescents with bipolar disorder [114]. Trials duration ranged between 4 and 16 weeks. Daily doses
ranged from 0.4 to 6.2 g/day of EPA and from 0.2 to 3.4 g/day of DHA. In the study performed by
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Gracious et al. ALA was administered at the dose of 0.5 g/day. Evaluation instruments were rather
homogeneous across studies (Hamilton Depression Rating Scale and Young Mania Rating Scale).
Among these seven RCTs, only two studies showed a significant effect of EPA and DHA
on depressive symptoms in bipolar disorder [111,113]. Patients treated with a combination of
EPA and DHA had a significantly longer period of remission than those treated with the placebo,
with significant improvement and remission of depressive symptoms [113] EPA in addition to standard
pharmacotherapy resulted superior to the placebo in reducing depressive symptoms in bipolar
depression [111]. Other five studies failed to show significant differences between single EPA, single
ALA or EPA plus DHA versus placebo on manic or depressive symptoms [107,109,110,113,114].
Four systematic reviews [7,105,115,116] and two meta-analyses [117,118] concluded that scarcity
of studies, rather small sample size and heterogeneity of trials duration and PUFAs dose represented
important limitations that did not allow to obtain reliable data on this topic. In summary, results
provided only initial evidence that omega-3 fatty acids in addition to standard medications could be
useful on depressive, but not manic symptoms of bipolar disorder [10]. Data of studies of bipolar
disorder are summarized in Table 3.
Table 3. Double-blind controlled trials of PUFAs in the treatment of bipolar disorders (depressive and
manic episodes).
Study Drugs and Dose Sample TreatmentDuration Results
Hirashima
et al., 2004
[109]
High dose: EPA, 5.0–5.2
g/day; DHA, 3.0–3.4 g/day;
other, 0.3–1.7 g/day
21 patients 4 weeks no significantdifferences
Chiu et al.,
2005
[107]
valproate 2 g/day and
4.4g/day EPA +
2.4 g/day DHA
16 newly hospitalised
patients in the acute
manic phase of bipolar
disorder
4 weeks no significantdifferences
Keck et al.,
2006
[110]
EPA 6 g/day in addition to at
least one mood stabilizer
121 patients with
bipolar depression or
rapid cycling bipolar
disorder
4 months no significantdifferences
Frangou
et al., 2006
[111]
ethyl-EPA 1 or 2 g/day
added to stable
psychotropic medications
75 patients 12 weeks
↓ depressive
symptoms measured
with HDRS
Murphy
et al., 2012
[112]
omega-3 fatty acids plus
cytidine, omega-3 fatty acid
plus placebo or only placebo
in addition to a
mood stabilizer
45 patients with type I
bipolar disorder 4 months
no benefits of omega-3
fatty acids on affective
symptoms
Stoll et al.,
1999
[113]
EPA 6.2 g/day + DHA
3.4 g/day 30 patients 16 weeks
↓ depressive
symptoms measured
with HDRS
Gracious
et al., 2010
[114]
ALA in addition to
psychotropic medication
children and
adolescent with
bipolar I or II disorder
16 weeks
significant
improvement of
overall symptom
severity compared
with placebo
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ethyl-EPA = ethyl-eicosapentaenoic
acid; ALA = α-linoleic acid; ↓ = decrease of; ↑ = increase of; HDRS: Hamilton Depression Rating Scale.
4.4. Omega-3 Fatty Acids in Anxiety Disorders
Similarly to major depression and bipolar disorder, inflammatory response is pertinent to the
pathophysiology of anxiety. As anxiety is linked to augmented production of pro-inflammatory
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cytokines and low levels of PUFAs in blood, omega-3 supplementation could induce a reduction of
anxious symptoms by decreasing inflammatory processes [119–121]. Anxiety disorders are a group of
disorders that shared symptoms of excessive or unreasonable fear and anxiety and related behavioral
abnormalities and neuro-vegetative symptoms.
RCTs available in literature on anxiety were performed in subjects with anxious symptoms
in other psychiatric disorders (ADHD, borderline personality disorder, major depressive disorder,
premenstrual syndrome, Tourette syndrome, substance abuse, Parkinson and Alzheimer diseases).
To our knowledge, there are not RCTs that have systematically investigated the effect of omega-3
PUFAs in anxiety disorders. Only a small trial [122] found a significant effect of EPA and DHA (doses
of EPA 2.2g/day and DHA 0.5g/day) on anxiety and inner tension in a sample of substance abusers.
The trial lasted 12 weeks. Anxiety continued to significantly decrease in the active treatment group
after three months discontinuation.
On this topic, one review [120] and one meta-analysis [123] were published. The review was
focused on the possible mechanisms of action of omega-3 PUFAs on anxiety. Results reported that
omega-3 fatty acids influence anxious symptoms by interleukin-6, neuroendocrine protein BDNF and
cortisol modulation [120]. The meta-analysis highlighted a modest anxiolytic effect of omega-3 fatty
acids in patients with several neuropsychiatric disorders or major physical illnesses [123].
4.5. Omega-3 Fatty Acids in Obsessive-Compulsive Disorder
Obsessive-compulsive disorder is characterized by the presence of recurrent and intrusive thoughts
(obsessions) and repetitive behaviors (compulsions) that patients are compelled to act in response
to obsessions.
No recent RCTs were published on supplementation of omega-3 fatty acids in obsessive-compulsive
disorder. The only available study was included in our previous review [10]. Results were unfavorable
as EPA (2 g/day) in augmentation of a stable dose of SSRIs (paroxetine or fluvoxamine or fluoxetine)
for 6 weeks was not associated to significant improvement of anxious, obsessive-compulsive and
depressive symptoms compared with the placebo [124]. Data are summarized in Table 4.
Table 4. Double-blind controlled trials of PUFAs in the treatment of post-traumatic stress disorder
(PTSD), obsessive-compulsive disorder (OCD) and substance use disorder.
PTSD
Study Drugs and Dose Sample TreatmentDuration Results
Matsuoka et al.,
2015
[125]
DHA 1.47 g/day +
EPA 0.147 g/day 110 patients 12 weeks
not superior to placebo for the secondary
prevention of PTSD symptoms
Matsuoka et al.,
2016
[126]
DHA 1.47 g/day +
EPA 0.147 g/day 110 patients 12 weeks
↑ erythrocyte level of EPA associated with
↓ PTSD symptoms
Matsumura et al.,
2017
[127]
DHA 1.47 g/day
and EPA
0.147 g/day
83 patients 12 weeks effective for the secondary prevention ofpsychophysiological symptoms of PTSD
OCD
Study Drugs and Dose Sample TreatmentDuration Results
Fux et al., 2004
[124]
EPA 2 g/day +
stable dose of SSRIs
11 patients with
OCD 6 weeks
no effect on anxious,
obsessive-compulsive and depressive
symptoms
Int. J. Mol. Sci. 2019, 20, 5257 13 of 32
Table 4. Cont.
Substance use disorder
Study Drugs and Dose Sample TreatmentDuration Results
Buydens-Branchey
& Barnchey,
2006
[122]
EPA + DHA at
high dose (3 g/day)
13 patients with
substance abuse 12 weeks ↓ anxious symptoms
Buydens-Branchey
et al., 2008
[128]
EPA + DHA at
high dose (3 g/day)
22 patients with
substance abuse 12 weeks ↓ anger and anxiety levels
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ↓ = decrease of; ↑ = increase of.
4.6. Omega-3 Fatty Acids in Post-Traumatic STRESS Disorder (PTSD)
Several investigations showed that PTSD is associated to a persistent and increased oxidative
stress with accelerated cellular aging. Loss of neural integrity in the hippocampus, amygdala, medial
prefrontal and anterior cingulate cortex and lower levels of PUFAs, in particular DHA, were found in
patients with PTSD [129,130]. A possible mechanism of action of these psychotropic agents in PTSD
symptoms is that they can facilitate fear-extinction learning and memories by facilitating hippocampal
neurogenesis [131–134]. In addition, PUFAs could reduce sympathetic nerve activity implicated in
the development of PTSD [135–138]. Post-traumatic stress disorder is defined by the onset of varying
symptoms following exposure to traumatic experiences. Re-experiencing emotional disturbances and
behavioral symptoms dominate clinical picture. While in recent years the interest for both PUFAs
efficacy and PTSD treatment has largely increased, RCTs that have evaluated the therapeutic role
of EPA and DHA in subjects with PTSD are still scarce. To our knowledge, only three studies are
available [125–127]. Two of these studies conducted two different analyses on patients of the same
trials [125,126]. Results on the efficacy of DHA are controversial. The first trial showed that DHA
supplementation was not superior to the placebo in preventing PTSD symptoms at 12 weeks after
traumatic event [125], but the re-analysis demonstrated that symptoms were improved in parallel
with an increase in blood EPA levels [126]. The second trial found that DHA at high dose (1.4 g/day)
with addition of low dose of EPA (0.1 g/day) improved tachycardia, but not psychiatric symptoms of
PTSD [127].
Due to the scarcity of data we cannot draw any conclusion on the opportunity to use omega-3
fatty acids in PTSD and further investigations are required collect data on this issue. In particular,
some findings suggest to test a composition of PUFAs with dominant EPA. Data of studies of PTSD are
summarized in Table 4.
4.7. Omega-3 Fatty Acids in Substance Use Disorder
Some investigations reported that inflammatory cascade induced by cytokines can be responsible
for the physical and psychological symptoms concomitant to craving. It is possible that omega-3 fatty
acids, such as EPA, neutralize these toxic effects in the brain [122,139]. To our knowledge, no recent
studies have been published after our previous review [10] on the efficacy of omega-3 fatty acids in the
treatment of substance use disorders. The only two studies available were conducted by the same
research group and showed that combination of EPA and DHA at high dose (3 g/day) produced a
positive effect on anxious symptoms related to addiction in 12 weeks of supplementation and during a
follow-up period of further 12 weeks [122,128].
Data in this field are too scarce to provide any reliable indication on the efficacy of PUFAs in
patients with substance use. Data of studies of substance use disorder are summarized in Table 4.
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4.8. Omega-3 Fatty Acids in Attention Deficit Hyperactivity Disorder (ADHD)
Recent investigations suggested a significant role of PUFAs on the immune system that is involved
in ADHD. PUFAs, in particular DHA deficiency in rats is involved with a change in behavioral
manifestations, such as increased motor activity and decreased learning ability [140,141]. In humans,
omega-3 fatty acids deficit in fetal brain could impinge normal development and represent a modifiable
risk factor for ADHD [142]. Attention deficit hyperactivity disorder is defined by a persistent condition
of lack of attention and hyperactivity or impulsivity that compromises functioning or development.
Fourteen RCTs were published on this topic [143–156]. Eleven studies tested the association
of EPA and DHA versus placebo with no other ADHD medications (stimulant or not stimulant
drugs) [144–150,153–156]. One trial evaluated the effect of DHA versus placebo in patients who
received other ADHD medications [143], one study tested EPA versus placebo in patients receiving
ADHD medications [152] and one RCT studied the efficacy of EPA versus placebo in subjects receiving
no other medications [151].
EPA and DHA were administered at a daily dose ranging between 0.08 and 0.65 g for EPA and
0.04 and 0.64 g for DHA. Duration of trials ranged between 12 and 30 weeks. Evaluation instruments
for patients’ assessment were homogeneous enough among studies. Most common rating scales
were: Conners’ parenting rating scale and Conners’ teacher rating scale; disruptive behavior disorders;
conduct for parents and the disruptive behavior disorders; attention for teachers. Parental and teachers’
ratings of symptoms showed weak consistency. A hypothesis to explain this discordance could be that
parents are more likely to observe changes in the child’s routine (i.e., daily activities such as getting
ready for school, getting dressed, completing homework), while teachers provided a report of the
children’s behavior at school, in terms of peer interactions and relationships. So, settings and child’s
activities that were evaluated by parents and teachers were significantly different.
Five studies did not find significant differences between EPA and DHA versus placebo in
improving ADHD symptoms in terms of hyperactivity and cognitive performances [143,145,146,149,
154]. Several other trials reported that PUFAs supplementation significantly improved parental reports
of global ADHD symptoms [144,147,148,151,152,155,156], inattention [144,147,151–153,155,156] and
hyperactivity [151,152,155]. In particular, higher doses of EPA (superior to 0.5 g/day) were found
effective on hyperactivity [151,152,155] and in one study single EPA was shown efficacious on
both hyperactivity and inattention [152]. On the other hand, omega-3 fatty acids did not reach
a significant effect in reducing teacher’s measures of inattention, hyperactivity and ADHD global
symptoms [151,153,155].
Concerning cognitive performances, omega-3 fatty acids supplementation showed efficacy in
improving omission and commission errors in cognitive tasks [143,147,148], but not memory and
information processing [143,147,148,155].
Two meta-analyses [157,158] concluded that omega-3 fatty acids supplementation in ADHD
produced small to modest significant reductions of symptoms, in particular when high doses of EPA
were used [157]. Among the three reviews available on this topic, the first was published by Gillies
and colleagues [159] and found little evidence that PUFAs had positive effects on the symptoms of
ADHD in children and adolescents. There was only limited indication that a combination of omega-3
and omega-6 fatty acids induced overall improvement. Two more recent reviews performed by
Gow et al. [160] and Chang et al. [161] reported more favorable conclusions, as they found some
evidence of efficacy of omega-3 fatty acids on symptoms and cognitive performances of ADHD patients.
The different conclusions of these reviews are difficult to explain, as no new trials were conducted
in recent years. Maybe differences in studies selection and data analysis are responsible for these
discrepancies. Data of studies of ADHD are summarized in Table 5.
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Table 5. Double-blind controlled trials of PUFAs in the treatment of attention deficit hyperactivity
disorder (ADHD).
Study Drugs and Dose Sample TreatmentDuration Results
Voigt et al.,
2001
[143]
DHA 0.345 g/day
versus placebo.
With ADHD medication
63 children
(6–12 years old)
with ADHD
4 months
no statistically significant improvement
in any ADHD symptoms compared to
placebo
Richardson
et al., 2002
[144]
EPA 0.186 g/day +
DHA 0.480 g/day +
linolenic acid 0.864 g/day +
arachidonic acid 0.042 g/day versus
placebo
41 children
with ADHD-like
symptoms
12 weeks
improvement of cognitive problems and
general behaviour in the group treated
with PUFAs than placebo
Stevens
et al., 2003
[145]
DHA 0.48 g/day +
EPA 0.08 g/day + arachidonic acid
0.04 g/day +
gamma-linolenic acid
0.096 g/day
versus placebo.
No ADHD medications
50 children with
ADHD-like
symptoms
4 months no significant differences
Hirayama
et al., 2004
[146]
EPA 0.1 g/day +
DHA 0.5 g/day
versus placebo
Mostly without ADHD medications
(only six subjects had been under
medications)
40 children
with ADHD 2 months
no evidence of efficacy of omega-3 fatty
acids compared to placebo
Sinn and
Bryan.,
2008
[147]
EPA 93 mg/day + DHA 29 mg/day +
gamma-linolenic acid
10 mg/day versus placebo.
No ADHD medications
132 children
(7 to 12 years)
with ADHD
improved in inattention, hyperactivity
and impulsivity in most ADHD scales in
parents reports; no improvement in
teachers reports
Limits: No ADHD diagnosis
(reported ADHD symptoms)
Vaisman
et al., 2008
[148]
EPA 0.156 g/day + DHA 0.095 g/day
or EPA 0.153 g/day + DHA 0.096
g/day or placebo
83 children with
ADHD 12 weeks
significantly improved executive
functioning
Johnson et al.,
2009
[149]
EPA 0.558 g/day + DHA 0.174 g/day +
gamma linoleic acid 0.06 g/day versus
placebo.
Only one patient with ADHD
medication
75 children and
adolescents
8–18 years old
with ADHD
3 months no evidence of efficacy of omega-3 fattyacids compared to placebo
Bélanger et al.
2009
[150]
EPA 0.02–0.025 g/kg/day + DHA
0.85–0.105 g/kg/day
versus placebo.
No ADHD medications
26 children 16 weeks
improvement in inattention and global
ADHD symptoms only in the first phase
of the study (weeks 0 to 15)
Gustafsson
et al., 2010
[151]
EPA 0.5 g/day 92 children (7 to 12years) with ADHD 15 weeks
two ADHD subgroups (oppositional and
less hyperactive/impulsive children)
improved symptoms
Perera et al.,
2012
[152]
omega-3 + omega-6 versus placebo.
With ADHD medications
98 children
(6 to 12 years)
with ADHD
diagnosis
6 months
improved behavior and learning in
restlessness, aggressiveness, completing
work and academic performance, but not
in inattention, impulsiveness and
cooperation with parents and teachers
Manor et al.,
2012
[153]
0.3 g of PS and 0.120 g of EPA + DHA
(EPA/DHA ratio of 2:1)
200 children with
ADHD 15 weeks improved ADHD symptoms
Milte et al.,
2012
[154]
EPA-rich oil (providing EPA 1.109
g/day and DHA 0.108 g/day,
DHA-rich oil (providing EPA 0.264
g/day and DHA 1.032 g/day)
versus an omega-6 PUFAs oil.
No ADHD medications
90 children
(7 to 12 years old)
with ADHD
4 months no statistically significant differencesbetween the two groups
Widenhorn-
Müller et al.,
2014
[155]
EPA 0.6 g/day + DHA 0.120 g/day.
No ADHD medications
95 children
(6 to 12 years)
with ADHD
16 weeks
improved working memory function, but
no effects on other cognitive measures or
behavioural symptoms in the study
population
Bos et al.,
2015
[156]
EPA 0.65 g/day + DHA 0.65 g/day
40 young boys (8
to14 years ) with
ADHD
16 weeks
↓ symptoms of ADHD, both for
individuals with ADHD and typically
developing children.
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; PS = phosphatidylserine; ↓ decrease of.
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4.9. Omega-3 Fatty Acids in Autism Spectrum Disorders
As some evidence suggested that autism may involve a cellular functional deficiency or imbalance
of omega-3 fatty acids [162–164], the number of investigations on the role of PUFAs as a treatment
option for autism spectrum disorders has grown up in the last years. Autism spectrum disorders
are characterized by prolonged deficits in social communication and relationships and by restricted
repetitive patterns of behavior and activities.
Eight RCTs are available [165–172]. Four of these trials tested the efficacy of combination of
EPA and DHA versus placebo at doses between 0.5 and 0.8 g/day for EPA and 0.2 and 0.7 g/day
for DHA [165–167,170], one study evaluated single DHA versus placebo [169], one compared a
large dose of arachidonic acid plus DHA or the placebo [168], one tested omega-3 fatty acids (EPA
and DHA) and omega-6 fatty acids (gamma linolenic acid) versus placebo [171] and one evaluated
the efficacy of vitamin D, DHA and both agents versus placebo [172]. Duration of trials varied
from 6 to 24 weeks. Five trials [165–168] assessed symptoms with the Aberrant Behavior Checklist,
three [166,169,170,172] used the Behavior Assessment System for Children and four [167,168,172] used
the Social Responsiveness Scale.
Results showed that omega-3 fatty acids supplementation improved some core symptoms of
autism, in particular hyperactivity [165–167] lethargy [165,166,168] and stereotypy [165–168]. One trial
reported a significant improvement in symptoms of irritability and in social domains (social awareness
and social communicative functioning) [172]. A possible beneficial effect of the association of omega-3
and omega-6 fatty acids was found in language development in one study performed in preterm
children exhibiting autism spectrum disorder symptoms [171].
The two available meta-analyses on efficacy of PUFAs in autism spectrum disorders are discordant
in their conclusions. The first [173] stated that no significant differences in severity of autism
symptoms were observed after treatment with PUFAs, except for lethargy in some studies. The second
meta-analysis [174] suggested a small but positive effect of omega-3 fatty acids in reducing hyperactivity.
Data concerning lethargy and stereotypy are statistically weak and need further confirmations.
In conclusion, the role of PUFAs in treatment of autism spectrum disorders is still debated.
The most favorable data concern the reduction of hyperactivity, followed by those supporting the
improvement of lethargy. Data of studies of autism spectrum disorders are summarized in Table 6.
Table 6. Double-blind controlled trials of PUFAs in the treatment of autism spectrum disorders.
Study Drugs and Dose Sample TreatmentDuration Results
Amminger et al.,
2007
[165]
EPA 0.84 /day +
DHA 0.7 g/day
13 children (aged 5 to 17 years)
with autistic disorders
accompanied by severe
tantrums, aggression or
self-injurious behavior
6 weeks
improvement of
hyperactivity and
stereotypy
Bent et al., 2011
[166]
1.3 g/day of omega-3
fatty acids (and 1.1 g
of DHA + EPA)
27 children (aged 3 to 8 years)
with autism spectrum disorder 12 weeks
improvement of
hyperactivity
Bent et al., 2014
[167]
1.3 g/day of omega-3
fatty acids (and 1.1 g
of DHA + EPA)
57 children with autism
spectrum disorder 6 weeks
improvement of
hyperactivity
Yui et al., 2012
[168]
large doses of ARA
(40 mg/day) added to
DHA (40 mg/day)
13 patients with autism
spectrum disorder 16 weeks
improved impaired
social interaction
by up-regulating
signal
transduction.
Voigt et al., 2014
[169]
DHA 0.2 g/day or
placebo
48 children (3 to 10 years) with
autism 6 months
no improvement
core symptoms of
autism
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Table 6. Cont.
Study Drugs and Dose Sample TreatmentDuration Results
Mankad et al., 2015
[170]
from 0.75 to 1.5 g/day
of EPA + DHA
38 children (2 to 5 years) with
autism spectrum disorder 6 months
no significant
differences
Sheppard et al.,
2017
[171]
Daily doses of
Omega-3-6-9 Junior
treatment (including
338 mg EPA, 225 mg
DHA, 83 mg GLA
and 306 mg total
omega-9 fatty acids)
31 children 18–38 months of
age born at ≤29 weeks of
gestation
3 months
evidence of efficacy
of omega-3 and -6
fatty acid
supplementation in
improving aspects
of early language
development in
children at risk for
ASD
Mazaheri et al.,
2019
[172]
vitamin D (2000
IU/day, VID),
omega-3 LCPUFA
(722 mg/day DHA,
OM) or both (2000
IU/day vitamin D +
722 mg/day DHA,
VIDOM)
117 children (2,5 to 8 years)
with autism spectrum disorder 12 months
vitamin D and
omega-3 LCPUFA
reduced irritability
symptoms; vitamin
D also reduced
hyperactivity
symptoms
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid VID = vitamin D; OM = omega-3;
VIDOM = vitamin D + omega-3; ARA = arachidonic acid.
4.10. Omega-3 Fatty Acids in Anorexia Nervosa
Abnormal levels of omega-3 and omega-6 fatty acids were observed in patients with anorexia
nervosa and in the activity of the enzyme responsible for desaturation of fatty acids [175,176]. Anorexia
nervosa is defined by three fundamental disturbances: Pronounced decreased of food intake, fear of
increase in weight and alteration in self-perception of shape. Several studies evaluated whether the
peripheral profile of PUFAs was different in subjects with eating disorders and healthy controls [177–180].
Five RCTs were performed to assess the efficacy of omega-3 in treating anorexia nervosa [181–185].
In all studies patients were predominantly constituted by females (85–100%). A wide range of omega-3,
omega-6 and omega-9 fatty acids was administered in the trials (alpha-linolenic acid, EPA, DHA,
stearidonic acid, adrenic acid, arachidonic acid, gamma linolenic acid, oleic acid). All articles used the
Eating Disorders Inventory to measure eating symptoms. Duration of trials ranged between 8 and 12
weeks. Daily dose ranged between 0.3 and 2.1g of EPA and between 0.2 and 0.6 g of DHA. Is it hard to
ascertain the daily dosages of other mixed PUFAs (omega-6, omega-9 fatty acids) used in the trials.
For patients with this diagnostic category findings were globally unfavorable, as all RCTs did
not find significant changes before and after PUFAs supplementation of eating symptoms, mood and
anxiety. Two studies [181,183] registered a significant change in body weight of patients with anorexia
after omega-3 fatty acids supplementation.
One recent meta-analysis was performed with a twofold objective: (1) To compare the differences
of PUFAs levels in patients with eating disorders and healthy subjects; (2) to verify potential beneficial
effects of these agents on eating dysfunction and related symptoms [186]. In conclusion, authors found
that there was an abnormal level of PUFAs in peripheral blood and tissues in patients with eating
disorders. In particular, PUFAs levels were higher in patients than in controls, except for lower levels
of omega-6 fatty acids. Concerning clinical effects, omega-3 fatty acids were active only in improving
body weight in anorexia, but no significant changes were observed in severity of eating dysfunction or
mood symptoms related to eating disorders. So, there is probably no point in specific supplementation
of omega-3 fatty acids. Data of studies of anorexia nervosa are summarized in Table 7.
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Table 7. Double-blind controlled trials of PUFAs in the treatment of anorexia nervosa.
Study Drugs and Dose Sample TreatmentDuration Results
Ayton et al., 2004
[181]
1 g/day E-EPA in
addition to
standard treatment
7 young patients
with anorexia
nervosa
3 months significant growth duringE-EPA supplementation
Barbarich et al.,
2004
[182]
tryptophan,
vitamins, minerals
and essential fatty
acids (DHA 0.6
g/day and
arachadonic acid
0.18 g/day) +
fluoxetine
26 patients with
anorexia nervosa 6 months
no significant difference in
weight gain, anxiety or
obsessive-compulsive
symptoms
Pirog-Balcerzak
et al., 2016
[183]
EPA 0.558 g/day
DHA 0.174 g/day +
gamma linolenic
acid 0.06 g/day,
vs. placebo
61 patients with
anorexia nervosa 10 weeks
not effective for depressive
and compulsive symptoms
Woo et al., 2017
[184]
EPA 300 mg/day +
DHA 200 mg/day +
standard treatment
21 patients with
eating disorders 8 weeks
significant increase in mean
percent ideal body weight,
but no significant differences
in eating disorder, anxiety
and depression symptoms
Manos et al., 2018
[185]
EPA 2.12 g/day +
DHA 0.6 g/day
24 adolescent
females with
anorexia nervosa
12 weeks no significant differences
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid.
4.11. Omega-3 Fatty Acids in Borderline Personality Disorder
Among personality disorders, the effect of omega-3 fatty acids was tested only in borderline
personality disorder. Borderline personality disorder can be defined a pervasive and long-lasting
condition of dysfunctional relationships, distorted self-image and unstable affective states and
impulsive-behavioral dyscontrol. For several years the nosological distinction between this disorder
and bipolar disorder was debated in research community. While there are some overlapping symptoms
including emotional instability and impulsivity, recent studies suggested that borderline personality
disorder and bipolar disorder can be distinguished as separate clinical entities [187]. As several
investigations showed a positive effect of omega-3 fatty acids on symptoms of impulsivity and
aggression in healthy and psychiatric subjects [188–190], efficacy of supplementation of these agents
has been verified in patients with borderline personality disorder, who often show impulsive-behavioral
dyscontrol and aggressiveness. To our knowledge five RCTs have been published [191–195]. Trials
were rather heterogeneous in choice of diagnostic criteria and contemporary administration of
conventional medications.
One study tested the efficacy of single EPA [191] while the remaining evaluated the effects of
combination of EPA and DHA. Daily doses ranged from 1 to 1.2 g for EPA and from 0.8 to 0.9 for
DHA. RCTs duration ranged from 8 and 12 weeks [191–193]. Two studies were follow-up studies: One
lasted 10 years [194] and one lasted 6 months [195]. Evaluation instrument to assess aggressiveness is
homogeneous (Modified Overt Aggression Scale (MOAS), while other rating scales are rather different
across trials (Montgomery-Åsberg Depression Rating Scale, Beck Depression Inventory, Borderline
Personality Disorder Severity Index, Barratt Impulsiveness Scale).
Omega-3 fatty acids with no adjunctive medications were found efficacious on aggression and
depressive symptoms [191] in comparison with the placebo. Moreover, these agents were shown
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effective in addition to standard pharmacotherapies in reducing depressive symptoms, self-injuries [192–
194], impulsivity [192–194] and outbursts of anger [193,195].
No reviews or meta-analyses were performed specifically on the use of omega-3 fatty acids in
personality disorders. Nevertheless, the Cochrane systematic review for the pharmacological treatment
of borderline personality disorder [196,197] concluded that omega-3 fatty acids (EPA and DHA) were a
therapeutic option for this personality disorder that had obtained some evidence of efficacy, together
with antipsychotics and mood stabilizers. Data of studies of borderline personality disorder are
summarized in Table 8.
Table 8. Double-blind controlled trials of PUFAs in the treatment of borderline personality disorder.
Study Drugs and Dose Sample TreatmentDuration Results
Zanarini and
Frankenburg, 2003
[191]
EPA 1 g/day
(with no standard psychiatric
therapies)
30 BPD females 8 weeks ↓ aggression,↓ depression
Hallahan et al.,
2007
[192]
EPA 1.2 g/day +
DHA 0.9 g/day
(added to the standard
psychiatric therapies)
49 patients with
self-defeating
behaviors
(39 BPD patients)
12 weeks
↓ depression,
↓ parasuicidal
behaviours,
↓ stress reactivity
Bellino et al., 2014
[193]
EPA (1.2 g/day) + DHA (0.6
g/day) in combination with
valproic acid (800–1300 mg/day)
versus
valproic acid (800–1300 mg/day)
(plasma range: 50–100 µg/mL)
43 BPD patients 12 weeks
↓ severity of BPDSI,
↓ impulsive
behavioural
dyscontrol,
↓ anger,
↓ self-mutilating
conduct
Gallagher et al.,
2017
[194]
n-3 PUFAs including EPA or
DHA
40 individuals who
self-harmed and 40
controls
10 years
↓ self-harm,
↓depressive
symptoms and ↓
impulsivity
Bozzatello et al.,
2018
[195]
EPA + DHA + valproic acid
34 patients with
borderline
personality
disorder
24 weeks ↓ outbursts ofanger
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ethyl-EPA = ethyl-eicosapentaenoic
acid; BPDSI = borderline personality disorder severity index; ↓ = decrease of; ↑ = increase of.
5. Adverse Effects
About 80% of RCTs included in this review evaluated adverse effects of PUFAs. Tolerability was
generally good for omega-3 fatty acids among studies. In clinical trials patients reported mild nausea,
diarrhea and a fishy aftertaste as main adverse events, but they did not induce discontinuation [74,198,
199]. These agents were recognized as safe also by the Panel of The European Food Safety Authority
(EFSA) that stated that EPA and DHA supplementation up to 5 g/day for a maximum of 16 weeks is
not dangerous for the general population [197], in terms of cardiovascular and bleeding risk [200–202],
glucose regulation [203–205], risk of activation of inflammatory response [206], lipid peroxidation and
cardiovascular risk [207]. However, patients on anticoagulant and antiplatelet medications require
additional monitoring during PUFAs supplementation [208].
Among RCTs included in this review there were no reports of severe and impairing adverse
events with EPA and DHA. In general, side effects registered in these trials were related to concomitant
psychotropic medications. High retention and adherence was reported (>80%).
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6. Conclusions
The present article is an update of our previous review [10] and is aimed to investigate the use of
PUFAs in treatment of psychiatric disorders. Our search was focused on randomized control trials that
have been conducted in this field over the last four decades.
While the role of PUFAs, in particular EPA and DHA, in psychiatric disorders has received in
recent years a growing interest and has been investigated in an increasing number of clinical trials,
a general agreement about their efficacy is lacking and the available evidence is controversial and
mainly inconclusive. One of the main obstacle to draw more definitive conclusions about the effects of
these agents consists of the wide heterogeneity across RCTs. Differences in methods are conspicuous
and concern sample size, diagnostic criteria, type and doses of PUFAs (i.e., EPA or DHA or combination
of the two omega-3 fatty acids or addition of omega-6 or omega-9 fatty acids), association with standard
medications, trials duration and follow-up evaluations.
The main evidence of efficacy for EPA and DHA has been obtained in mood disorders. In particular,
supplementation with omega-3 fatty acids was found efficacious in reducing depressive symptoms in
major depressive disorders and, in association with standard medications, in bipolar disorder. Initial
data in adolescents and elderly depressed patients are promising, but further studies in larger samples
are required. On the other hand, EPA and DHA failed to improve depressive symptoms in perinatal
depression. It is noticeable that the Canadian Network for Mood and Anxiety Treatments (CANMAT)
clinical guidelines for the management of adults with major depressive disorder attributed to PUFAs
level 1 evidence of efficacy in depression, but precautionary recommended these agents as second-line
monotherapy for mild to moderate major depression and as adjunctive therapy to antidepressants for
moderate to severe major depressive disorder.
Results concerning schizophrenia and related psychotic disorders are still debated and available
evidence does not allow either to reject or support the use of omega-3 fatty acids in psychotic patients.
Omega-3 fatty acids supplementation could be more efficacious in the early phases of schizophrenia
(first episode of psychosis) than in chronic phases of the disorder in addition to antipsychotic treatment.
In particular, EPA and DHA could be useful in reducing the progression of illness in subjects at high
risk to develop psychosis.
In borderline personality disorder supplementation of omega-3 fatty acids obtained favorable
results on some core symptoms: Impulsivity, self-injuries and anger. Trials in this field are promising,
but are still limited. Small to modest beneficial effects of omega-3 fatty acids in ADHD were found
by several studies that were performed in this disorder. In particular, studies that tested EPA at high
doses or the association of omega-3 and omega-6 fatty acids got more favorable findings in terms of
reduction of hyperactivity and, to a lesser degree, improvement of cognitive performance. In autism
spectrum disorders the number of clinical trials and reviews increased since our previous review [10],
but a consensus among investigators has not been obtained, yet. Most favorable findings concern the
reduction of hyperactivity, followed by the improvement of lethargy in children with autism. Omega-3
supplementation cannot be recommended as an alternative to support behavioral therapies for autism
spectrum disorder. It can be proposed only to complement other therapies in this clinical population.
Efficacy of omega-3 fatty acids was not specifically assessed in patients with anxiety disorders (i.e.,
panic disorder, social phobia, agoraphobia), but a modest anxiolytic effects of omega-3 fatty acids in
patients with several neuropsychiatric disorders or major physical illnesses was observed. PTSD is a
disturbance that has acquired considerable interest in the last decades, but studies on the use of PUFAs
in these patients are too scarce to propose any indication. PUFAs were not found efficacious in treating
symptoms of obsessive-compulsive disorder, eating disorders and substance use disorder.
Concerning tolerability, the large majority of RCTs reported that omega-3 fatty acids were well
tolerated. The most common, but mild side effects reported in clinical trials were mild nausea, diarrhea
and a fishy aftertaste. The intake of EPA and DHA up to 5 g/day and up to 16 weeks seems to be safe
in terms of bleeding risk, glucose regulation, infection risk and lipid alterations.
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While the results are not consistent enough, available findings on the effects of omega-3 fatty
acids in several psychiatric disorders are promising in terms of clinical efficacy and good tolerability.
In our opinion, a fundamental issue remains unsolved. When (in what kind of psychiatric disorder?
at what level of severity of symptoms?) can these agents be administered in monotherapy and in
which cases is the association with standard pharmacotherapies and/or psychosocial interventions
preferable? In addition, which medications and which models of psychotherapy are better indicated
in combination with PUFAs to treat specific psychiatric disorders? To date, these questions cannot
be answered as the majority of trials do not provide specific information on the adjunctive therapies
(doses, duration, type of medications or psychotherapies).
In conclusion, a major challenge for researchers in this field is to design and conduct further RCTs
with rigorous methods to definitively demonstrate that omega-3 fatty acids supplementation can be
considered a reliable option to treat some specific psychiatric disorders and to make clear which are
the better modalities to provide these agents in single clinical conditions.
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